Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open‐label study
Year: 2024
Type: article
Study design: Clinical Trial
Abstract: Acalabrutinib is a selective, second-generation Bruton tyrosine kinase inhibitor. In this open-label, parallel-group study, patients with relapsed/refractory (R/R) follicular lymphoma (FL) were randomised to either acalabrutinib monotherapy or acalabrutinib plus rituximab. An additional cohort of patients with treatment-naive (TN) FL received only the acalabrutinib-rituximab combination. Acalabrutinib-rituximab was well tolerated and active in R/R and TN FL; in the TN cohort the overall response rate was 92.3% with most remissions lasting over 4 years. Acalabrutinib monotherapy was also well tolerated and active in R/R FL. These results support further study of acalabrutinib alone and in combination with rituximab in FL.
Source: British Journal of Haematology
DOI: 10.1111/bjh.19787
Institutions: The University of Texas MD Anderson Cancer Center, Norton Healthcare, Weill Cornell Medicine, University of Chicago Medical Center, Rush University Medical Center, NewYork–Presbyterian Hospital, AstraZeneca (United Kingdom), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,940
Funder: AstraZeneca
OpenAlex ID: W4402723866